Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sacubitril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME known ✓ | P08473 | 12/20 | 0.63 |
| ▸ | ACE | P12821 | 4/20 | 0.63 |
| ▸ | MMEL1 | Q495T6 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sacubitril SCHEMBL21239956 | 1.00 | MME (0.63) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL29554043 | 1.00 | MME (0.63) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL21239966 | 0.98 | MME (0.63) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL21239967 | 0.98 | MME (0.63) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL28471087 | 0.98 | MME (0.63) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL29490800 | 0.98 | MME (0.63) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL1908525 | 0.90 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL18059568 | 0.90 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL18059569 | 0.90 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL8214132 | 0.90 | MME (0.77) | MMEACEMMEL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3763373-B1 | PHARMACEUTICAL FORMULATION AND USE THEREOF | WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) | 2025-12-17 | — | — | EP | claimed |
| EP-3524250-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A NEUTRAL ENDOPEPTIDASE (NEP) INHIBITOR AND AN AZILSARTAN ESTER DERIVATIVE AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) | 2025-07-16 | — | — | EP | claimed |
| CN-110237071-B | Pharmaceutical preparation and use thereof | 武汉朗来科技发展有限公司 | 2022-03-22 | — | — | CN | claimed |
| US-20210052579-A1 | PHARMACEUTICAL PREPARATION AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2021-02-25 | — | — | US | claimed |
| EP-3763373-A1 | PHARMACEUTICAL FORMULATION AND USE THEREOF | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2021-01-13 | — | — | EP | claimed |
| US-20200038379-A1 | PHARMACEUTICAL COMPOSITION | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2020-02-06 | — | — | US | claimed |
| CN-110237072-A | The preparation method of pharmaceutical composition | 武汉朗来科技发展有限公司 | 2019-09-17 | — | — | CN | claimed |
| EP-3524250-A1 | PHARMACEUTICAL COMPOSITION | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2019-08-14 | — | — | EP | claimed |
| EP-3763373-B1 | PHARMACEUTICAL FORMULATION AND USE THEREOF | WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) | 2025-12-17 | — | — | EP | disclosed |
| EP-3611160-B1 | AMMONIUM CARBOXYLATE COMPOUND, CRYSTAL FORM AND AMORPHOUS SUBSTANCE THEREOF, AND PREPARATION METHOD THEREFOR | WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) | 2023-03-29 | — | — | EP | disclosed |
| CN-109803657-B | Pharmaceutical composition | 武汉朗来科技发展有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-110237072-B | Process for preparing pharmaceutical composition | 武汉朗来科技发展有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-110237071-B | Pharmaceutical preparation and use thereof | 武汉朗来科技发展有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-11161803-B2 | Ammonium carboxylate compound, crystalline form, amorphous form and preparation method thereof | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2021-11-02 | — | — | US | disclosed |
| EP-3763373-A1 | PHARMACEUTICAL FORMULATION AND USE THEREOF | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2021-01-13 | — | — | EP | disclosed |
| US-20200055812-A1 | AMMONIUM CARBOXYLATE COMPOUND, CRYSTALLINE FORM, AMORPHOUS FORM AND PREPARATION METHOD THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2020-02-20 | — | — | US | disclosed |
| EP-3611160-A1 | AMMONIUM CARBOXYLATE COMPOUND, CRYSTAL FORM AND AMORPHOUS SUBSTANCE THEREOF, AND PREPARATION METHOD THEREFOR | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2020-02-19 | — | — | EP | disclosed |
| US-20200038379-A1 | PHARMACEUTICAL COMPOSITION | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2020-02-06 | — | — | US | disclosed |
| CN-110237072-A | The preparation method of pharmaceutical composition | 武汉朗来科技发展有限公司 | 2019-09-17 | — | — | CN | disclosed |
| EP-3524250-A1 | PHARMACEUTICAL COMPOSITION | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2019-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161803-B2 | Ammonium carboxylate compound, crystalline form, amorphous form and preparation method thereof | ACMSD, ADSL, AMD1 | MME 3513/4885ACE 110/4885MMEL1 4455/4885 |
| US-20200055812-A1 | AMMONIUM CARBOXYLATE COMPOUND, CRYSTALLINE FORM, AMORPHOUS FORM AND PREPARATION METHOD THEREOF | ACMSD, ADSL, AMD1 | MME 3513/4885ACE 110/4885MMEL1 4455/4885 |
| US-20200038379-A1 | PHARMACEUTICAL COMPOSITION | MME, ANPEP, TMPRSS15 | MME 1/4885ACE 32/4885MMEL1 107/4885 |
| US-20210052579-A1 | PHARMACEUTICAL PREPARATION AND USE THEREOF | PREP, PEPD, FURIN | MME 4/4885ACE 152/4885MMEL1 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.